Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche's efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Competition is also growing beyond the two incumbents, with companies including AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) racing to develop new treatments. DON'T MISS: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.